Delving into the Latest Updates on Delamanid with Synapse

This is an investigational, prospective, multicenter, single-arm, open label trial. The goal of this clinical trial is to evaluate the efficacy and safety of a 6-month all-oral regimen, consisting of Bedaquiline (BDQ, B), Delamanid (DLM, D), Linezolid (LZD, L), Levofloxacin (LFX) or Clofazimine (CFZ, C), or BDLLfxC regimen, to treat rifampin-resistant pulmonary tuberculosis (RR-TB) in Chinese teenagers and adults (aged 12 years or above). The main questions it aims to answer are:
* Is BDLLfxC regimen effective to treat RR-TB in Chinese participants?
* Is BDLLfxC regimen safe in Chinese RR-TB participants? Participants will take BDLLfxC regimen to treat their RR-TB. There will be no additional hospital visits, laboratory tests or radiological examinations other than routine clinical practice.

Start Date27 Nov 2024

Sponsor / Collaborator

Shanghai Huashan Hospital

[+1]

CTRI/2024/09/073225

/ Not yet recruitingNot ApplicableIIT

Cost-effectiveness, drug utilization study and safety of bedaquiline and delamanid based regimen in pediatric and adolescent MDR-TB patients in a tertiary care hospital. - NIL

Start Date02 Sep 2024

Sponsor / Collaborator-

CTRI/2024/08/071882

/ Not yet recruitingNot ApplicableIIT

Comparing the cost-effectiveness of bedaquiline, delamanid, linezolid and their combinations based on Quality-Adjusted Life-Years (QALYs) versus Disability-Adjusted Life-Years (DALYs) in patients with multidrug-resistant and extended drug-resistant tuberculosis at tertiary care hospital in South Gujarat - NIL

Start Date21 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Delamanid

Login to view more data

100 Translational Medicine associated with Delamanid

Login to view more data

100 Patents (Medical) associated with Delamanid

Login to view more data

1,464

Literatures (Medical) associated with Delamanid

01 Jun 2025·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination

Review

Author: Matteelli, Alberto ; Rossi, Luca ; Rossi, Benedetta ; Lovatti, Sofia

Multidrug-resistant tuberculosis (MDR-TB), the deadliest form of tuberculosis (TB), has been included in the 2024 World Health Organization (WHO) priority list of antibiotic-resistant bacterial pathogens owing to its severe public health implications. Almost two billion people worldwide are infected with Mycobacterium tuberculosis; however, the share of MDR-M.tuberculosis remains uncertain. Mathematical modeling estimates that MDR-TB affects nearly three in every 1000 people worldwide, highlighting the urgent need to address TB preventive treatment (TPT) for contacts of MDR-TB cases. Before 2018, close monitoring of contacts of people with MDR-TB was recommended rather than TPT. However, considering the ethical and public health concerns associated with leaving infected individuals untreated, the WHO updated its guidelines in 2018, 2020, and 2022. Despite the limited evidence at the time, the WHO suggested considering quinolone-based TPT for selected high-risk cases. To close this gap in evidence, two large-scale prospective randomized controlled trials were conducted: VQUIN (VQUIN MDR Australia New Zealand Clinical Trials Registry number, ACTRN12616000215426) and TB-CHAMP (TB-CHAMP ISRCTN Registry number, ISRCTN92634082). Both trials evaluated the efficacy of levofloxacin (Lfx) compared with a placebo for MDR-TB after household exposure in adults and children. A combined meta-analysis of the two trials showed a 60% reduction in TB incidence in the Lfx group, and the difference was statistically significant. Based on these results, in 2024, the WHO recommended the use of 6 months of daily Lfx as a TPT for contacts exposed to MDR/rifampicin-resistant TB. This regimen is cost-effective, safe, demonstrates good efficacy, and does not interact with HIV therapies. Despite these promising results, pre-extensively drug-resistance (XDR)-TB (MDR-TB with documented resistance to quinolones) remains an emerging concern. Two ongoing trials will address this challenge: the PHOENIx trial (PHOENIx-MDR TB NCT03568383), which will evaluate the efficacy of delamanid compared with isoniazid for preventing M/XDR-TB after household exposure, and the BRANCH-TB trial (NCT0656848), which will assess the efficacy and safety of 1 month of bedaquiline regimen compared with WHO-recommended TPT regimens. Preventing MDR/rifampicin-resistant TB remains a significant challenge for the global elimination of TB. Although the recent WHO recommendation for 6 months of daily Lf is a promising step, expanding the TPT options for pre-XDR TB and addressing drug intolerance are critical. Ongoing and new trials are essential to develop alternative treatment and achieve TB elimination.

01 May 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Upregulation of HDAC3 mediates behavioral impairment in the bile duct ligation model of hepatic encephalopathy

Article

Author: Aggarwal, Aanchal ; Rishi, Vikas ; Elipilla, Pavani ; Gupta, Shiwangi

Hepatic encephalopathy (HE), an outcome of chronic liver disease is characterized by behavioral impairments. The present study investigated the role of HDAC-mediated transcriptional regulation causing behavioral impairments in the bile duct ligation (BDL) model of HE. Post-BDL surgery in rats, dynamic alterations in liver function tests, liver morphology were observed. In BDL rats, histological staining in brain demonstrated reduced neuronal viability and warped neuronal architecture. Additionally, BDL animals showed impaired spatial learning, memory, and increased anxiety in the open field, Barnes maze, and Y maze tests. Further, the Golgi cox staining revealed a significantly altered spine density and spine clustering patterns of granular neuron in dentate gyrus of BDL rats. Concordantly, a significant downregulation of memory encoding genes was also observed in BDL rats that may account for aberrant behavior. Molecular analysis of modifiers, such as HDAC, showed significant changes in the expression of HDAC3 and HDAC6 in both the cortex and hippocampus of BDL rats. Upregulation of HDAC3 promoted its localization on the promoter of genes like c-Fos, NPAS4, Arc, and others, likely causing their decreased expression. Our findings suggest that increased HDAC3 activity downregulates key synaptic plasticity and memory-related genes, potentially driving neurobehavioral changes in BDL rats.

01 May 2025·TUBERCULOSIS

Functional analysis of genetic mutations in ddn and fbiA linked to delamanid resistance in rifampicin-resistant Mycobacterium tuberculosis

Article

Author: Kang, Gisu ; Lee, Gyeong In ; Lee, Seung Heon ; Park, Youngsuk ; Kim, Hyejin ; Hwang, Byoung Oh ; Yang, Jeong Seong ; Kim, Hyeon-Su ; Kim, Seungmo

The connection between genetic mutations linked to delamanid resistance and phenotypic resistance remains unclear. We assessed the phenotypic effects of delamanid-resistant mutations in the Mycobacterium tuberculosis H37Rv strain through gene disruption using homologous recombination and complementation tests. Delamanid resistance was assessed by determining the minimum inhibitory concentration (MIC) via the 7H9 microdilution method. Sanger sequencing identified mutations, and conservation of the mutated residues was predicted through multiple sequence alignments of orthologs. A total of 116 isolates with MIC ≥0.025 μg/mL were analyzed, among which mutations were identified in the ddn and fbiA genes. Isogenic strains were generated based on these mutations. The ddn or fbiA isogenic strains with Ala77Val, Gly81Ser, Asn25fs, and Leu104Phe in fbiA had MICs ≥0.8 μg/mL, indicating resistance. In contrast, the ddn isogenic strain with Pro12Ala had an MIC of 0.012 μg/mL, showing susceptibility, while Gly96Asp in fbiA had an MIC of 0.1 μg/mL, indicating resistance. All mutations, except for Pro12Ala, were conserved in the protein sequences of both FbiA and Ddn and their mycobacterial orthologs. The characterization of these mutations provides insights into the mechanisms of delamanid resistance, which may inform the development of optimized treatment strategies.

8

News (Medical) associated with Delamanid

06 Feb 2025

·www.drugs.com

Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB

THURSDAY, Feb. 6, 2025 -- Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin -resistant tuberculosis , according to a study published in the Jan. 30 issue of the New England Journal of Medicine . Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted a phase 3, multinational, noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis to five nine-month oral regimens, including combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). A total of 754 participants were randomly assigned to one of five combinations or standard therapy; 699 were included in the modified intention-to-treat analysis and 562 were included in the per-protocol analysis. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was −12 percentage points. The researchers found that 80.7 percent of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. In the modified intention-to-treat population, the risk difference between standard therapy and each of the four new regimens was noninferior: 9.8, 8.3, 4.6, and 2.5 percentage points for BCLLfxZ, BLMZ, BDLLfxZ, and DCMZ, respectively. In the per-protocol population, the differences were similar, apart from DCMZ, which was not noninferior. Across the regimens, the proportion of participants with grade 3 or higher adverse events was similar. "The results of this trial support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis," the authors write. Two authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 3Clinical Result

14 Nov 2024

·www.globenewswire.com

ACTG Presents Two Studies Providing Insights Into TB Treatment at Union Conference on Lung Health

LOS ANGELES, Nov. 14, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced two oral presentations on tuberculosis (TB) therapy that took place at The Union Conference on Lung Health 2024, in Bali, Indonesia. The oral presentation “Six Months is a Lot of Time to Lie:” Disclosure and Treatment Preferences Among Participants in a Tuberculosis Therapeutic Trial was presented by Faith Mugodhi, M.Sc., H.S.W., University of Zimbabwe-Clinical Trials Research Centre (UZ-CTRC). The oral presentation High Prevalence of Fluoroquinolone Resistance and katG Mutations in Adult Index Patients in a Multinational MDR-TB Prevention Trial was presented by Soyeon Kim, Sc.D., IMPAACT Senior Statistician, Frontier Science Foundation. “ACTG is honored to share these important findings with the many global stakeholders who are gathered in Indonesia at the Union Conference,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles. “TB is one of ACTG’s key research priorities, as the disease remains a leading killer worldwide. The knowledge gained from the research presented today has the potential to inform our approach to TB treatment and ultimately improve the experiences of people with TB.” “Six Months is a Lot of Time to Lie:” Disclosure and Treatment Preferences Among Participants in a Tuberculosis Therapeutic Trial was a sub-study that investigated experiences around disclosure and treatment preferences among participants in ACTG 5362. Also known as CLO-FAST, this multi-center treatment-shortening trial for drug-susceptible TB randomized individuals to receive either a three-month regimen containing clofazimine (which can be associated with skin hyperpigmentation) or the six-month standard of care. The sub-study consisted of exploratory, qualitative in-depth interviews with 23 participants undergoing treatment in CLO-FAST from India, Malawi, and Zimbabwe. This presentation reported that all sub-study participants with TB had voluntarily disclosed their TB status to at least one other person. Nearly half of participants (43.5 percent) feared inadvertent disclosure of their status due to their treatment and attendance at the TB clinic; 80 percent (n=8) of these were taking clofazimine. One in five participants reported experiencing stigma or discrimination as a result of inadvertent disclosure, including being treated badly by their families or communities. Today’s presentation also found that participants had different preferences around the kind of treatment they received. Two-thirds (n=15) of participants reported that they would prefer the shortened regimen even if one of the medications led to a change in their skin color, while one-third (n=8) reported a preference for the longer regimen. That preference was associated with anticipation of stigma and beliefs that a longer regimen is more potent against TB. These data suggest that anticipated stigma and pre-existing beliefs may be important in understanding treatment preferences. High Prevalence of Fluoroquinolone Resistance and katG Mutations in Adult Index Patients in a Multinational MDR-TB Prevention Trial is an analysis from the PHOENIx study, an ongoing clinical trial evaluating the efficacy and safety of preventive treatment for multi-drug resistant TB (MDR-TB) with delamanid compared to isoniazid, conducted jointly by the ACTG and IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) networks. (IMPAACT is a global collaboration of investigators, institutions, community representatives, and other partners, with a mission to improve health outcomes for infants, children, and adolescents as well as pregnant and postpartum people who are impacted by or living with HIV by evaluating novel treatments and interventions for HIV and its complications for tuberculosis and other related complications, through the conduct of high-quality clinical trials.) Knowledge of drug susceptibility in people with active TB is important for the provision of both efficacious treatment for their TB disease and TB preventive treatment for their contacts. This presentation sought to describe drug resistance patterns in adults with MDR-TB whose household members were approached to participate in PHOENIx. Between June 2019 and October 2023, 1,353 adults with documented MDR-TB were enrolled from 28 sites and 13 countries in Africa, Asia, and Central and South America. Among those for whom isoniazid mutation data were available, 73 percent (n=783 of 1078) had high-level resistance (katG mutations). Among the 699 participants who had fluoroquinolone drug-susceptibility testing available, 20 percent (n=139) had fluoroquinolone resistance. These results suggest that it is important to have non-fluoroquinolone options for TB preventive treatment. They also support the relevance of the PHOENIx trial’s evaluation of delamanid vs. isoniazid for TB preventive treatment in high-risk household contacts of adults with MDR-TB. Primary results of the clinical trial are anticipated in 2027. CLO-FAST is led by John Metcalfe, M.D., Ph.D., M.P.H., University of California San Francisco; Samuel Pierre, M.D., Les Centres Gheskio, Haiti; and Kimberly Scarsi, Pharm.D., M.S., University of Nebraska Medical Center and study drugs were supplied by the Global Drug Facility. PHOENIx is jointly conducted by ACTG and IMPAACT and led by Gavin Churchyard M.B.Ch.B., M.Med., Ph.D., The Aurum Institute NPC; Amita Gupta, M.D., M.H.S., Johns Hopkins University; Anneke Hesseling, M.B.Ch.B., M.Sc., Ph.D., Desmond Tutu TB Centre - Stellenbosch University; and Susan Swindells, M.B.B.S., University of Colorado. Delamanid is supplied for PHOENIx by Otsuka Pharmaceutical Company, Ltd. ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair). The studies are sponsored by the National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG) under award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634. IMPAACT is also funded by NIAID with support and co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH). About ACTGACTG is the world’s largest and longest running clinical trials network focused on HIV and other infectious diseases and the people living with them. It is funded by NIAID and collaborating NIH Institutes. Founded in 1987, ACTG conducts research to improve the management of HIV and its comorbidities; develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis B, and emerging infectious diseases. It comprises thousands of dedicated researchers, staff, and community members who are pursuing research into novel treatments and cures for infectious diseases at hundreds of locations across four continents, with the ultimate goal of advancing science that meaningfully impacts the lives of the people we serve. Disclaimer: This content is solely the responsibility of ACTG and does not necessarily represent the official views of the NIH. Media Contact:Jenna Conley, ACTGjenna@conleycommunications.net

Clinical StudyClinical Result

22 Mar 2024

·www.otsuka.co.jp

Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment

Otsuka Pharmaceutical, Co. Ltd. And our U.S.-based subsidiary Otsuka Pharmaceutical Development & Commercialization, Inc., announce that interim data from a Phase 2b/c trial exploring quabodepistat (QBS), in combination with delamanid and bedaquiline, for the treatment of pulmonary tuberculosis (TB) is positive and may shorten the duration of TB treatment for patients. QBS is an investigational anti-tuberculosis compound which has a new mechanism of action that interferes with the cell-wall structure of the bacteria causing TB.1,2 Worldwide, TB is the second leading infectious fatal disease after COVID-19. The interim analysis -- which was presented at the 2024 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado in early March -- demonstrated that a four-month regimen of QBS, in combination with delamanid and bedaquiline, can achieve similar safety and efficacy, compared to the six-month, standard-of-care four-drug regimen in participants with drug-susceptible TB.3 These results show that sputum culture conversion rates -- or effectiveness of the treatment combination in killing the bacteria -- at the end of treatment in the pooled QBS-based, three-drug regimen arms were on par with existing standard four-drug TB treatment. The three-drug QBS-based arms were well-tolerated, with no serious treatment emergent adverse events reported, related to the regimens.3 The ongoing study, supported by Otsuka and the Bill & Melinda Gates Foundation, is being held across six clinical research sites in South Africa. Otsuka and the foundation have been collaborating to end TB worldwide, and the foundation contributed to initial funding for the early development of quabodepistat.2,3 "Otsuka is encouraged by these positive interim data and is pleased to continue working with the support of the Bill & Melinda Gates Foundation to identify safe and effective treatment options for patients living with tuberculosis," said Masanori Kawasaki, global project leader of TB Project at Otsuka Pharmaceutical. "We are deeply thankful to the patients, their families and the clinicians who participated in this important clinical research study." The trial (NCT05221502) was a multicenter, Phase 2b/c, open-label, randomized, dose-finding trial designed to evaluate the safety and efficacy of a four-month regimen of OPC-167832 (quabodepistat) in combination with delamanid and bedaquiline in patients with drug-susceptible pulmonary tuberculosis in comparison with six months standard treatment. Full results of this phase 2b/c, randomized trial are expected by the end of 2024.2,3 *1Hariguchi N et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19. *2Dawson R et al. Quabodepistat in Combination with Delamanid and Bedaquiline in Participants with Drug-Susceptible Pulmonary Tuberculosis: protocol for a multicenter, phase 2 b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy. Trials. 2024 Jan 19;25(1):70. *3Dawson R et al. A 4-month Regimen of Quabodepistat, Delamanid and Bedaquiline for Pulmonary TB: Interim Results. Conference on Retroviruses and Opportunistic Infections (CROI), 5 March 2024, Denver, Co., USA; Abstract no. 163. *4World Health Organization, Tuberculosis key facts　https://www-who-int.libproxy1.nus.edu.sg/news-room/fact-sheets/detail/tuberculosis

Phase 2Clinical ResultPhase 3

100 Deals associated with Delamanid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09785	Delamanid	J04AK06	DB11637

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Tuberculosis	China	Otsuka Pharmaceutical Co., Ltd.	17 Feb 2018
Pulmonary Tuberculosis	Japan	Otsuka Holdings Co., Ltd.	04 Jul 2014
Tuberculosis, Multidrug-Resistant	European Union	Otsuka Novel Products GmbH	27 Apr 2014
Tuberculosis, Multidrug-Resistant	Iceland	Otsuka Novel Products GmbH	27 Apr 2014
Tuberculosis, Multidrug-Resistant	Liechtenstein	Otsuka Novel Products GmbH	27 Apr 2014
Tuberculosis, Multidrug-Resistant	Norway	Otsuka Novel Products GmbH	27 Apr 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multidrug resistant pulmonary tuberculosis	Phase 3	Estonia	Otsuka Pharmaceutical Development & Commercialization, Inc.	02 Sep 2011
Multidrug resistant pulmonary tuberculosis	Phase 3	Latvia	Otsuka Pharmaceutical Development & Commercialization, Inc.	02 Sep 2011
Multidrug resistant pulmonary tuberculosis	Phase 3	Lithuania	Otsuka Pharmaceutical Development & Commercialization, Inc.	02 Sep 2011
Multidrug resistant pulmonary tuberculosis	Phase 3	Moldova	Otsuka Pharmaceutical Development & Commercialization, Inc.	02 Sep 2011
Multidrug resistant pulmonary tuberculosis	Phase 3	Peru	Otsuka Pharmaceutical Development & Commercialization, Inc.	02 Sep 2011
Multidrug resistant pulmonary tuberculosis	Phase 3	Philippines	Otsuka Pharmaceutical Development & Commercialization, Inc.	02 Sep 2011
Multidrug resistant pulmonary tuberculosis	Phase 3	South Africa	Otsuka Pharmaceutical Development & Commercialization, Inc.	02 Sep 2011
HIV Infections	Phase 2	India	Otsuka Pharmaceutical Development & Commercialization, Inc.	30 Jan 2018
HIV Infections	Phase 2	South Africa	Otsuka Pharmaceutical Development & Commercialization, Inc.	30 Jan 2018
HIV Infections	Phase 2	Tanzania	Otsuka Pharmaceutical Development & Commercialization, Inc.	30 Jan 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02619994 (MDR-END, CTgov)	Phase 2	Tuberculosis, Multidrug-Resistant	214	Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm)	xizswmxhqb = kdhsrmhnpo vqoebzgadt (dnehgfppbq, breldqibwa - mgnyobgwsr) View more	-	03 Jan 2025
				Levofloxacin+Linezolid+Delamanid+Pyrazinamide (Experimental Arm)	xizswmxhqb = riisvoavxr vqoebzgadt (dnehgfppbq, dqbuenbqcu - fyjnljfcnj) View more
NCT03896685 (endTB-Q, Pubmed)	Phase 3	Tuberculosis, Multidrug-Resistant	324	Bedaquiline, Linezolid, Clofazimine, Delamanid	qqryaowkkz(tpjfmqceix) = battmtnbew rtmqwsqzuj (ipyyytttpv )	Positive	30 Nov 2023
				Contemporaneous WHO standard of care for pre-XDR TB	qqryaowkkz(tpjfmqceix) = bhrfmuxsmi rtmqwsqzuj (ipyyytttpv )
ATS2023	Not Applicable	Tuberculosis, Multidrug-Resistant	785	With new TB drugs	zxaizbebrm(idzssiuqmv) = thleudmdts kodssppnnq (wvtxlhcncy ) View more	Positive	21 May 2023
				Without new TB drugs	zxaizbebrm(idzssiuqmv) = rynpyggrxg kodssppnnq (wvtxlhcncy ) View more
NCT01859923 \| NCT01856634 (Pubmed \| Antimicrob Agents Chemother) Manual	Phase 1/2	Tuberculosis, Multidrug-Resistant	37	Delamanid	bomfwbjrbx(iakrwbsdps) = cttjrgddmt jtphxgxlae (kodzpfyxtz ) View more	Positive	11 Apr 2022
NCT00685360 (CTgov)	Phase 2	Extensively Drug-Resistant Tuberculosis \| Multidrug resistant pulmonary tuberculosis	481	Placebo+Delamanid (Delamanid 100 mg BID + OBR)	wtdcvinums = wrcjsxrajy morpocghay (hbxvbvswfi, pslxrficao - wcfpjlhmdp) View more	-	01 Dec 2021
				Optimized Background Regimen (OBR)+Delamanid (Delamanid 200 mg BID + OBR)	wtdcvinums = gyjkskwezg morpocghay (hbxvbvswfi, cpkycebhks - eauusnrcfi) View more
NCT01131351 (CTgov)	Phase 2	Drug-Resistant Tuberculosis \| Multidrug resistant pulmonary tuberculosis	10	OBR+Delamanid (Delamanid 250 mg BID + OBR)	whyzrxhbci = aevvzoqorj wixtnafvse (etihkjzavq, witcebicgf - cwzbluicxj) View more	-	11 Nov 2021
				OBR+Delamanid (Delamanid 300 mg BID + OBR)	whyzrxhbci = ixinlbvnpz wixtnafvse (etihkjzavq, nizndyacip - hjnqylbqjb) View more
NCT02573350 (CTgov)	Phase 2	Multidrug resistant pulmonary tuberculosis \| Tuberculosis, Multidrug-Resistant	213	OBR+Delamanid (Delamanid 100 mg BID + OBR)	seqhsryxhq = xcyxslgiwg ytthuajppd (wykipgiwqh, jjmtamoybo - prmgwwoqvc) View more	-	01 Nov 2021
				OBR+Delamanid (Delamanid 200 mg BID + OBR)	seqhsryxhq = quorpuqmpo ytthuajppd (wykipgiwqh, nctcvcmyhs - znqtyareis) View more
NCT02583048 (ACTG A5343, Pubmed \| Lancet Infect Dis)	Phase 2	Rifampicin resistant tuberculosis	84	Bedaquiline	fpnjkpumjm(yhutmunxlp) = isjgdnxhhm zmhhpnfqkc (xvcaszuwbx, 71 - 97)	Positive	12 Feb 2021
				Delamanid	fpnjkpumjm(yhutmunxlp) = tgitmhidet zmhhpnfqkc (xvcaszuwbx, 65 - 95)
NCT01859923 (CTgov)	Phase 2	Tuberculosis, Multidrug-Resistant	37	Optimized Background Regimen (OBR)+Delamanid (Group 1: 12 to 17 Years of Age)	uhiqebmauk = zmphnxyjoh amfrnxvphz (zdoeyvpmiw, hdaftzowyu - lzfmkakdad) View more	-	23 Nov 2020
				Optimized Background Regimen (OBR)+Delamanid (Group 2: 6 to 11 Years of Age)	uhiqebmauk = qviwdmmulq amfrnxvphz (zdoeyvpmiw, bfaxbshuge - mbyclcrkhp) View more
NCT02583048 (ACTG A5343, CTgov)	Phase 2	HIV Infections \| Multidrug resistant pulmonary tuberculosis	84	Dolutegravir+Bedaquiline (Arm 1: Bedaquiline)	geixsukrbk(bqwqdmjuhq) = ibirwelulr ecdafmimlg (pzthgpuncb, mmvgxsofsl - fqjdfonpik) View more	-	29 Jan 2020
				Dolutegravir+Delamanid (Arm 2: Delamanid)	geixsukrbk(bqwqdmjuhq) = oloyqeuvcn ecdafmimlg (pzthgpuncb, xltwdbfqas - qxhqxethrs) View more